Evolus reported Q2 2026 revenue of $84.1 million, delivering its third consecutive quarter of positive adjusted EBITDA and prompting the company to raise full-year 2026 guidance. The earnings beat consensus forecasts, with shares rising on the announcement.
Business & M&A
Evolus Posts Third Straight Profitable Quarter
Q2 revenue hit $84.1M with positive adjusted EBITDA; full-year guidance lifted.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Third consecutive quarter of positive adjusted EBITDA signals Jeuveau franchise stabilization.
For medspa owners, this matters because Evolus's profitability inflection signals stabilization in the Jeuveau franchise after years of margin pressure. A healthier manufacturer typically means more stable rebate programs and less aggressive price-cutting to defend share. The Evolus Rewards loyalty program remains a key variable—program terms can shift without notice and directly hit your per-unit economics, so cross-check your rebate tier against the current public terms before assuming your margin baseline.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.